Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Severe hemophilia A defined as \<1 IU/dL (\<1%) endogenous FVIII~* Male \<12 years of age and weight ≥13 kg~* History of at least 50 documented prior exposure days to FVIII~* No current, or history of, inhibitor development to FVIII~Key Exclusion Criteria:~* Other coagulation disorders in addition to Hemophilia A~* History of anaphylaxis associated with any FVIII or IV immunoglobulin administration~NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).